131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Inclusion Criteria:

• Histologically confirmed marginal zone B-cell lymphoma
• relapsed or refractory patients after treatment including chemotherapy, radiation therapy, and surgery
• Eastern Cooperative Oncology Group performance status ≤ 2
• age≥ 20 years
• More than one measurable lesion (More than 2cm sized lesion in conventional CT scan, More than 1cm sized lesion in spiral CT or contrast-enhanced PET/CT )
• Adequate renal function (serum creatinine ≤ 2.0 mg/dl or Ccr ≥ 60 ml/min)
• Adequate hepatic function (serum bilirubin ≤ 2.0 mg/dl , AST/ALT ≤ 3 upper normal limit)
• Adequate bone marrow reservoir (ANC ≥1,500/㎕, platelet count≥ 75,000/㎕)
• patient who agree the purpose and intention of this clinical trial

Exclusion Criteria:

• recent (<5 years) history of other malignancy or unrecovered from the disease (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded)
• hemodynamically unstable due to the recent (<12 months) history of severe heart disease such as myocardial infarction
• acute complications of severe lung or metabolic disease
• Combined severe neurological or psychiatric disease
• Unrecovered from infection or other medical disease
• Recent (<30 days) history of enrollment of other clinical trial
• Pregnant or breast-feeding woman
• women of childbearing potential and men not employing adequate contraception at least for 1 year
• Previous history drug allergy to the content of 131I-rituximab
• Infection(sepsis, pneumonia, viral infection, etc) (inactivated hepatitis B carrier can be enrolled)